Immunome, Inc. (IMNM)

NCM – Цена в реальном времени. Валюта: USD

27.99

+1.74 (6.63%)

При закрытии: Aug 12, 2026, 4:00 PM EDT

28.87

+0.88 (3.14%)

До открытия: Aug 13, 2026, 4:01 AM EDT

11.08.2026

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended June 30, 2026, and provided a business update. “We continue to execute against our strategy of building a diversified targeted oncology company with multiple opportunities to bring needed therapies to patients,” said Clay B. Siegall, Ph.D., President and Chief Executive Of.

06.08.2026

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on August 3, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 176,500 shares of common stock to nine new employees under the Company's 2024 Induc.

Видео

No Data

There is no data to display

Пресс-релизы

11.08.2026

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

06.08.2026

Immunome, Inc. (IMNM)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Immunome, Inc. (IMNM)

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Immunome, Inc. (IMNM)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Immunome, Inc. (IMNM)

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)